

77/LG/SE/JUNE/2022/GBSL

June 06, 2022

To
The Manager (CRD)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001

To
The Manager
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code : 509079

Scrip Symbol : GUFICBIO

Dear Sir/ Madam,

Subject: Intimation of Press Release

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith a press release being issued by the Company on the captioned subject, the content of which is self-explanatory.

The same is submitted for public dissemination and for your records.

Thanking you,

Yours faithfully,

For Gufic Biosciences Limited



Ami Shah
Company Secretary
Membership No. A39579



Encl.: As above



GUFIC BIOSCIENCES LIMITED EYES TO GRAB MAJOR SHARE OF RS. 3000 CRORE LYOPHILIZED ANTIBIOTICS & ANTIFUNGAL MARKET IN INDIA

Gufic Biosciences Limited ("Gufic"), a fast-growing pharmaceutical player recognized for its innovative, high-quality pharmaceutical and herbal products, has targeted to capture major share of Rs. 3000 crore lyophilized antibacterial market in India. Gufic has launched **New Drug Delivery System: Dual Chamber Bags** at affordable price for the first time in India.

Contributing immensely to the government's ambitious Make in India drive, Gufic has collaborated with its European counterpart to manufacture this new technology indigenously in India. Until now the dual chamber bags have been largely imported in India at a very high cost to the patients. On the contrary, Gufic has not only launched high-quality Dual Chamber Bags at an affordable and pocket friendly price, these New Drug Delivery System products even have longer shelf-life.

Dr. Debesh Das, COO-Domestic Formulation said, "We are committed to reduce the country's dependency on imported products especially in critical care segment. Moving ahead with this vision we have launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price. As we are experiencing rapidly growing demand for our product we look forward to grab major market share in this particular segment."

These Dual Chamber Bags launched by Gufic are 2-Chamber IV Bags made up of polypropylene (DEHP free) with a peelable aluminium foil allowing the storage of unstable drugs which needs reconstitution just before the administration to the patient. The peelable seal separates lyophilized (or powder) drug and its diluent. Moreover, the product complies with the US and EU pharmacopoeias and it is manufactured in ISO7 clean room under cGMP.

Features and benefits of Dual Chamber Bags (DCB) by Gufic :

- It reduces risk of bloodstream infections and thereby ensures Patient's safety.
- Stability of the drug is much more in DCB rather than vials as it provides complete protection from light & moisture
- The bag's closed system ensures that the product is sterile and avoids risks of contamination during handling.
- No Nitrosamines used- No risk of Cancer in diverse organs and tissues.
- DCB, tubing & twist-off port are DEHP free- No risk of Cancer, birth defects & other reproductive harms.
- Glue free-Eradicates the risk of interaction with drug product.
- Prefilled with intended dosage and diluent in 2 separate bags- Accurate dosing, easy handling, seal integrity and high stability
- Individualized treatment regimens-Avoids hospital contamination & provides high stability and convenience- Thus significantly improving product quality & patient compliance.
- Provides high stability- Avoids leachability, free of airborne bacterial contaminants & needle stick injuries.

One of the most important USPs of these ready-to-use Dual Chamber Bags by Gufic is that they prevent contamination and protects the potency and efficacy of the drug. These bags also offer ease of handling at the time of reconstitution and also help in avoiding the dilution errors since the drug is present with the exact required quantity of the diluent to be used. It can be reconstituted just before administration by simply peeling off the aluminium foil and folding & squeezing the bag, thus the diluent enters the drug chamber and mixes with the drug. It is then directly administered as IV infusion to the patient with the help of IV tubes.

Recognised as one of the largest manufacturers of Lyophilized injections in India, Gufic has a fully automated lyophilisation plant. The company's lyophilized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments, among others. Its products are supplied to all the major hospital chains and leading medical facilities.

About Gufic

Gufic is engaged in the research and development, manufacturing, marketing, distribution and sale of pharmaceutical and allied products. Gufic is known and respected for innovative and high quality pharmaceutical and herbal products along with a wide range of Active Pharmaceutical Ingredients (APIs). Gufic is one of the fastest growing company amongst the top 100 pharma companies in India and is also one of the largest manufacturers of Lyophilized injections in India and have a fully automated lyophilisation plant. Gufic's lyophilized products are available in Therapy areas like Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor (PPI). Gufic is now augmenting its global focus by deepening its presence in the priority markets of India, Germany, Switzerland, South Africa, Russia, Canada, Europe and other key countries within the emerging market territories. Gufic aims at providing lifesaving drugs to people at affordable prices with no compromise in its quality. Gufic is a WHO-GMP, EU GMP, ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia TGA, Colombia INVIMA and Uganda NDA approved company with a total capacity of 30 million lyophilized vials per annum.